Cablivi Approved for Rare Clotting Disorder

WEDNESDAY, Feb. 6, 2019 — Cablivi (caplacizumab-yhdp) injection has been approved by the U.S. Food and Drug Administration to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and deadly disorder that causes blood…
Source: Topamax